KromaTiD Blog2023-03-22T10:28:23-06:00

KromaTiD’s Dark Lab Files: A Blog

CB-011: A Gene-Edited CAR-T Therapy Against Multiple Myeloma

Multiple myeloma (MM) is a complex blood cancer affecting plasma cells. Patients can experience bone damage and fractures, kidney failure resulting from protein buildup, anemia and more frequent infections, among other symptoms. Given the disease's serious impacts to quality and length of life, scientists [...]

March 15, 2024|Tags: , , |

Genomic Insights into Cancer from the 100,000 Genomes Cancer Program

The 100,000 Genomes Cancer Program is a UK government research initiative aimed at integrating genomic data with clinical information to gain insights into the molecular basis of cancer. It involves the sequencing of genomes from 100,000 cancer patients, encompassing a diverse range of cancer [...]

March 8, 2024|Tags: , , |

In Situ 3D Scaffold-Mediated T-Cell Transduction

Use of three-dimensional (3D) scaffolds in vivo to influence cell behavior is not a new concept. However, recently reported work innovatively applies the approach to the field of cancer immunotherapy1. The use of 3D scaffolds loaded with lentiviral vectors (LVs) to program host T-cells [...]

March 1, 2024|Tags: , , , , |

Natural Killer T (NKT) Cells in Cancer Immunotherapy

While T cells engineered with chimeric antigen receptors (CAR-T cells) have revolutionized the landscape of hematologic malignancy treatment, their efficacy against solid tumors remains limited. However, there is a promising alternative: Natural Killer T (NKT) cells. These innate-like T lymphocytes are unique contenders in [...]

Automating CAR-NK Cell Manufacturing

Acute myeloid leukemia (AML) is a neoplastic process characterized by its aggressive nature and limited treatment options. Too many AML patients are unable to achieve long-term remission with current therapies, fueling the search for novel strategies. CAR-NK cells offer a compelling solution, leveraging the [...]

February 16, 2024|Tags: , , |

Title

Go to Top